ReviewJournal of translational medicine2026
The role of PPP2R1A variants in gynecologic malignancies: a paradigm shift in immuno-oncology.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundProtein Phosphatase 2 A (PP2A), a key tumor suppressor, is frequently inactivated in cancer through mutations in its scaffold-encoding gene, PPP2R1A. This is particularly common in aggressive gynecologic malignancies, specifically uterine serous carcinoma (USC) and ovarian clear cell carcinoma (OCCC). A compelling paradox has emerged: while these mutations are potent oncogenic drivers, they are also powerful predictive biomarkers for an exceptional response to immune checkpoint inhibitor (ICI) therapy. MAIN BODY: This study provides a comprehensive narrative review of the literature to dissect the dual role of PPP2R1A in gynecologic cancers. This review elucidates the molecular pathogenesis and immune activation mechanisms of PPP2R1A mutations, while also outlining emerging therapeutic strategies targeting this pathway.
conclusionsThe dual function of PPP2R1A mutations represents a paradigm shift in the field. Understanding this pathway provides crucial new insights that are poised to advance the future of precision immuno-oncology for patients with gynecologic cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.